Rapport Therapeutics is a clinical-stage biotechnology company that discovers and develops precision medicines for neurological disorders.
Rapport Therapeutics has raised $250.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2025.
Rapport Therapeutics's investors include ARCH Venture Partners, Cormorant Asset Management, Perceptive Advisors, Sofinnova Investments, Fidelity.
Rapport Therapeutics is headquartered in Boston, United States.
Rapport Therapeutics is a clinical-stage biotechnology company that discovers and develops precision medicines for neurological disorders.
Rapport Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Rapport Therapeutics — Funding & Investors." VCBacked, September 9, 2025, https://www.vcbacked.co/company/rapport-therapeutics. Accessed July 18, 2026.
VCBacked. (2025). Rapport Therapeutics — Funding & Investors. Retrieved July 18, 2026, from https://www.vcbacked.co/company/rapport-therapeutics
{{cite web |title=Rapport Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/rapport-therapeutics |website=VCBacked |access-date=July 18, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated